2024 Speakers Alessio Cantore Group Leader San Raffaele-Telethon Institute for Gene Therapy Alex Goraltchouk Chief Operating Officer Remedium Bio Alex Tracy Chief Technical Officer Code Biotherapeutics Allison Dane Senior Director, Research & Development AskBio Amanda Placone Senior Director, External Innovation & Early Commercial Strategy Eli Lilly & Co. Brett Hoffman Senior Scientist II, Novel Capsid Discovery Voyager Therapeutics Campbell Murray Partner Agent Capital Caroline Xu Co-Founder & Chief Executive Officer ViGeneron GmbH Christopher Lim Chief Business Development & Financial Officer GenixCure Costanza Gorini Senior Research Analyst Hanson Wade Daniel Cohen Senior Director, Head of Vector Optimization Spark Therapeutics Darin Falk Chief Scientific Officer Lacerta Therapeutics, Inc. David Goertsen Senior Scientist Capsida Biotherapeutics Don Haut Chief Business Officer EG427 Eric Kelsic Founder & Chief Executive Officer Dyno Therapeutics Jing Liao Head of Vector Technology Alexion Pharmaceuticals Joseph Nabhan Chief Scientific Officer Vesigen Therapeutics Jun Xie Associate Professor UMass Medical School Leszek Lisowski Unit Head Of Translational Vectorology Unit Children’s Medical Research Institute Lucia Faccio Partner Sofinnova Partners Marc Abrams Chief Scientific Officer Carbon Biosciences Morten Sogaard President, Astellas Gene Therapy & Technical Operations Astellas Gene Therapies Inc Paul Heppenstall Founder Borea Therapeutics Robert Lin Chief Executive Officer Avista Therapeutics Rodolphe Clerval Chief Executive Officer Coave Therapeutics Roxanne Croze Senior Director, Vector Innovation 4D Molecular Therapeutics Simon Pacouret Senior Research Scientist, Vector Engineering Group, Deverman Lab The Broad Institute of MIT & Harvard Teddy Jégu Director of Research EG427 Tetsuya Yamagata Chief Scientific Officer Modalis Therapeutics